Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Shire will pay roughly $5.9 billion to acquire the biotech firm Dyax. The deal will deepen Shire’s roster of treatments for hereditary angioedema (HAE), a rare, genetic immune system disorder. Dyax adds the approved HAE drug Kalbitor, and DX-2930, a plasma kallikrein inhibitor that is expected to start Phase III trials in HAE later this year. Shire, which already markets the HAE treatment Cinryze, says DX-2930 could generate annual sales of up to $2 billion. Shire claims that the deal for Dyax will not disrupt its ongoing pursuit of the specialty pharmaceuticals firm Baxalta, which this summer rejected an unsolicited $30 billion bid from Shire.
This article has been sent to the following recipient: